Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
GoodRx is now publicly available to trade. The stock opened at $46, nearly 40% above it's IPO price of $33.
Launched in 2011, GoodRx allows customers to compare prescription drug prices. It's since become a household name, which may be one of the reasons that the stock has been getting so much buzz. If you're planning to invest, here's how you can buy in.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $6.30 |
|---|---|
| 52-week range | $5.62 - $48.05 |
| 50-day moving average | $10.71 |
| 200-day moving average | $27.16 |
| Wall St. target price | $10.99 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.04 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.3 from 2022-06-29
| 1 week (2022-06-24) | -9.48% |
|---|---|
| 1 month (2022-05-31) | -20.95% |
| 3 months (2022-03-29) | -67.17% |
| 6 months (2021-12-31) | -80.72% |
| 1 year (2021-07-01) | -81.79% |
|---|---|
| 2 years (2020-06-27) | N/A |
| 3 years (2019-06-27) | N/A |
| 5 years (2017-06-27) | N/A |
Valuing Goodrx Holdings Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Goodrx Holdings Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Goodrx Holdings Inc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $66.5 million.
The EBITDA is a measure of a Goodrx Holdings Inc's overall financial performance and is widely used to measure a its profitability.
To put Goodrx Holdings Inc's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $788.3 million |
|---|---|
| Operating margin TTM | 4.84% |
| Gross profit TTM | $698.7 million |
| Return on assets TTM | 1.56% |
| Return on equity TTM | -1.91% |
| Profit margin | -1.86% |
| Book value | $1.99 |
| Market capitalisation | $2.4 billion |
TTM: trailing 12 months
We're not expecting Goodrx Holdings Inc to pay a dividend over the next 12 months.
You may also wish to consider:
GoodRx Holdings, Inc. , through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
